anti-HPV16 E7/HLA-A*0201 TCR T cell therapy (Rutgers University)

N/A

Report date: 2025/01/26 19:06:33

Base Information

Drug Nameanti-HPV16 E7/HLA-A*0201 TCR T cell therapy (Rutgers University)
Drug Alias NameE7 TCTR-T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulatorsProtein E7 modulators
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha ChainProtein E7
Therapy Area/IndicationsVulvar DiseasesPenile NeoplasmsVaginal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRutgers University
China Registration ClassN/A

Develop Information

Active CompaniesRutgers University
Inactive CompaniesN/A
Active IndicationsVulvar DiseasesPenile NeoplasmsVaginal Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A